Trust Company’s Cytokinetics CYTK Stock Holding History

Trust Company’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$852	Hold	10	–	–	﹤0.01%	630
2026 Q1	$659	Hold	10	–	–	﹤0.01%	646
2025 Q4	$635	Buy	+10	New	+$622	﹤0.01%	625

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Trust Company's CYTK Position: Q2 2026 in Review

Trust Company held its Cytokinetics (CYTK) position steady in Q2 2026 at 10 shares worth $852. The position accounts for ﹤0.01% of the portfolio, ranked #630.

Trust Company first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Trust Company held 10 shares of Cytokinetics worth $852 as of Q2 2026.
Trust Company left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up ﹤0.01% of Trust Company's portfolio in Q2 2026, its #630 holding.
Trust Company first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Trust Company's 13F filing for Q2 2026, filed 10 Jul 2026.